Shots:

• The global companies modernize their alliance as of Jan 01- 2020 to completely focus their expertise and investment on the development and commercialization of Jardiance (empagliflozin) for T2D- HF and CKD  
• As per the amended agreement- the companies will revise the margin sharing structure for ongoing payments from Jan 01- 2020. Trajenta (linagliptin) and Basaglar (insulin glargine) will remain to be the part of the alliance- with each partner to take exclusive control of its own product i.e- BI to be responsible for Trajenta and Lilly for Basaglar
• Jardiance (PO- qd) is a highly selective SGLT2 inhibitor and is the first T2D therapy to include risk reduction in CV death data demonstrated in EMPA-REG OUTCOME study

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Pharmafile